CHO Pharma, Inc. (TPEX:6586)
Taiwan · Delayed Price · Currency is TWD 110.50
-1.50 (-1.34%)
Aug 26, 2026, 1:54 PM CST
CHO Pharma Balance Sheet
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Cash & Equivalents | 60.25 | 52.09 | 21.81 | 203.79 | 505.66 | 777.98 |
Short-Term Investments | 1,900 | 2,008 | 2,344 | 2,399 | 538.9 | 538.9 |
Cash & Short-Term Investments | 1,960 | 2,060 | 2,366 | 2,603 | 1,045 | 1,317 |
Cash Growth | -11.97% | -12.93% | -9.10% | 149.17% | -20.68% | -13.66% |
Accounts Receivable | - | - | 0.75 | - | - | 0.06 |
Other Receivables | 6.09 | 8.03 | 5.05 | 2.09 | 0.09 | 0.08 |
Receivables | 6.09 | 8.03 | 5.8 | 2.09 | 0.09 | 0.14 |
Other Current Assets | 59.53 | 55.66 | 45.68 | 38.23 | 34.8 | 23.62 |
Total Current Assets | 2,026 | 2,124 | 2,417 | 2,643 | 1,079 | 1,341 |
Property, Plant & Equipment | 16.26 | 26.11 | 36.43 | 8.2 | 19.74 | 37.23 |
Other Intangible Assets | 420.2 | 420.2 | 424.8 | 431.8 | 497.23 | 509.93 |
Other Long-Term Assets | 3.04 | 2.68 | 2.67 | 3.02 | 5.84 | 5.91 |
Total Assets | 2,465 | 2,573 | 2,881 | 3,086 | 1,602 | 1,894 |
Liabilities
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Accrued Expenses | - | 84.1 | 95.75 | 99.43 | 150.85 | 113.04 |
Current Portion of Leases | 7.33 | 14.59 | 14.31 | - | 11.7 | 13.87 |
Current Unearned Revenue | 5.14 | 5.33 | - | - | - | - |
Other Current Liabilities | 79.77 | 5.04 | 6.12 | 6.6 | 6.35 | 6.31 |
Total Current Liabilities | 92.24 | 109.06 | 116.19 | 106.03 | 168.9 | 133.22 |
Long-Term Leases | - | - | 14.59 | - | - | 11.7 |
Other Long-Term Liabilities | - | - | 1.8 | 4.8 | 4.8 | 4.8 |
Total Liabilities | 92.24 | 109.06 | 132.58 | 110.83 | 173.7 | 149.71 |
Shareholders' Equity
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Common Stock | 2,140 | 2,140 | 2,140 | 2,140 | 1,840 | 1,839 |
Additional Paid-In Capital | 621.92 | 828.57 | 1,130 | 1,688 | 135.73 | 410.58 |
Retained Earnings | -386.17 | -502.23 | -518.31 | -850.41 | -544.32 | -502.76 |
Comprehensive Income & Other | -2.73 | -2.73 | -2.7 | -2.75 | -2.79 | -3.25 |
Shareholders' Equity | 2,373 | 2,464 | 2,749 | 2,975 | 1,429 | 1,744 |
Total Liabilities & Equity | 2,465 | 2,573 | 2,881 | 3,086 | 1,602 | 1,894 |
Additional Metrics
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Jun '26 Jun 30, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Total Debt | 7.33 | 14.59 | 28.9 | - | 11.7 | 25.56 |
Net Cash (Debt) | 1,953 | 2,046 | 2,337 | 2,603 | 1,033 | 1,291 |
Net Cash Growth | -11.44% | -12.47% | -10.21% | 151.99% | -20.02% | -13.16% |
Net Cash Per Share | 9.15 | 9.56 | 10.92 | 13.60 | 5.61 | 7.02 |
Filing Date Shares Outstanding | 213.69 | 214.01 | 214.01 | 214.01 | 183.99 | 183.94 |
Total Common Shares Outstanding | 213.69 | 214.01 | 214.01 | 214.01 | 183.99 | 183.94 |
Working Capital | 1,934 | 2,015 | 2,301 | 2,537 | 910.56 | 1,207 |
Book Value Per Share | 11.11 | 11.51 | 12.84 | 13.90 | 7.76 | 9.48 |
Tangible Book Value | 1,953 | 2,044 | 2,324 | 2,543 | 931.34 | 1,234 |
Tangible Book Value Per Share | 9.14 | 9.55 | 10.86 | 11.88 | 5.06 | 6.71 |
Machinery | - | 120.54 | 112.08 | 107.99 | 104.61 | 96.59 |
Leasehold Improvements | - | 21.48 | 20.72 | 20.38 | 19.82 | 18.6 |